Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia
NCT07061951Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Primary endpoint: Best Objective Response Rate up to 5 years. Started May 2026; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07061951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061951.